INCB086550

INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research[1].

Product Specifications

CAS Number

[2230911-59-6]

Product Name Alternative

PD-1/PD-L1-IN-8

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

PD-1/PD-L1

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/incb086550.html

Purity

99.80

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : 83.33 mg/mL (ultrasonic; adjust pH to 3 with HCl)

Smiles

N#CC1=C2C(N=C(C3=C(C(C4=C(C(NC5=NC=CC6=C5N=CC(CN7CC[C@H](C7)O)=C6)=CC=C4)C)=CC=C3)C)O2)=CC(CN8C[C@@H](CC8)C(O)=O)=C1

Molecular Formula

C41H39N7O4

Molecular Weight

693.79

Precautions

H302, H315, H319

References & Citations

[1]WU LIANGXING, et al. BENZOOXAZOLE DERIVATIVES AS IMMUNOMODULATORS. WO2018119266A1.|[2]Koblish HK, et al. Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer Discov. 2022 Jun 2;12 (6) :1482-1499.